Agenda
- Jump to:
- At a Glance
- Day 1
- Day 2
- Day 3
- Print-friendly Format
Day 1 - Monday, March 9, 2015
1:00 |
FDA Regulatory Fundamentals 101 With Ethics Session |
Day 2 - Tuesday, March 10, 2015
7:45 |
Registration and Continental Breakfast |
8:45 |
Co-Chairs’ Opening Remarks and Brief Overview of FDA Practice |
9:00 |
The Nature of the Approval Process |
10:15 |
Morning Coffee Break |
10:30 |
Understanding the Clinical Trial Process for Drugs and Biologics |
11:30 |
Drugs and Biologics: Labeling |
12:30 |
Networking Luncheon |
1:45 |
Part 1 – Patents, Trademarks and Other IP Protections and Mechanisms |
3:00 |
Afternoon refreshment break |
3:15 |
Part 2 – Hatch-Waxman and BPCIA Overview |
4:45 |
The Drug Supply Chain Security Act – Summarizing the Act and Its Effect on FDA Practice |
5:30 |
Conference Adjourns to Day Two |
Day 3 - Wednesday, March 11, 2015
Day 1 - Monday, March 9, 2015
1:00 |
FDA Regulatory Fundamentals 101 With Ethics SessionSeth A. Mailhot 1:00 Fundamentals of FDA Regulatory Law Aimed at providing a primer to professionals who have limited or no
experience working with FDA on regulatory matters, this workshop
will provide you with a basic overview of FDA regulations and will
prepare you for the more in-depth discussions that will take place
throughout the conference. Topics addressed during this workshop
will set the stage for the main conference by helping you thoroughly
comprehend the structure of the FDA and walk you through the preapproval,
approval, and post-approval process. Get the background you
need to flow seamlessly into the conversations at FDA Boot Camp.
4:00 Resolving Ethical Challenges Encountered During the Drug Approval Process This one hour program will explore ethical issues that may arise in the context of communications with FDA on behalf of clients. The program is based on scenarios involving situations in which FDA requires full disclosure of adverse information and authority. For example:
|
Day 2 - Tuesday, March 10, 2015
7:45 |
Registration and Continental Breakfast |
8:45 |
Co-Chairs’ Opening Remarks and Brief Overview of FDA PracticeSeth A. Mailhot Geoffrey M. Levitt |
9:00 |
The Nature of the Approval ProcessGeoffrey M. Levitt Rx Drugs
Biological Products
OTC Products
PREAPPROVAL AND APPROVAL |
10:15 |
Morning Coffee Break |
10:30 |
Understanding the Clinical Trial Process for Drugs and BiologicsDaniel A. Kracov
|
11:30 |
Drugs and Biologics: LabelingAlan G. Minsk The labeling of the drug/biological product is the final stage of the approval process. The labeling affects what you can do post-approval. It is the point of transition between the approval process and post-approval world.
|
12:30 |
Networking LuncheonPatent and IP Overview for Drugs and Biologics: Understanding The Connection Between FDA Regulation and IP and Related |
1:45 |
Part 1 – Patents, Trademarks and Other IP Protections and MechanismsJill K. MacAlpine, Ph.D. Donna M. Meuth
|
3:00 |
Afternoon refreshment break |
3:15 |
Part 2 – Hatch-Waxman and BPCIA OverviewKurt R. Karst Christopher E. Jeffers Ph.D. Drugs
Biologics
Exclusivity for Combination Products
|
4:45 |
The Drug Supply Chain Security Act – Summarizing the Act and Its Effect on FDA PracticeMichael Walsh
|
5:30 |
Conference Adjourns to Day Two |
Day 3 - Wednesday, March 11, 2015
7:00 |
Continental Breakfast |
7:45 |
Co-Chairs’ Opening Remarks and Recap of Day OnePOST-APPROVAL |
8:00 |
cGMPs: Drugs and Biologics (current Good Manufacturing Practices)Kirsten Mayer
|
9:00 |
Medical Devices: Classifications, the Essentials of the Premarket Review Process, and Post-Market Requirements and ConcernsSeth A. Mailhot Jennifer L. Bragg FDA’s Risk-Based Classification Scheme
The Premarket Review Process
Post-Market Requirements and Concerns
MEDICAL DEVICES |
10:00 |
Morning Coffee Break |
10:15 |
Using FDA’s Citizen Petition Process and Litigation to Achieve Market SuccessChad A. Landmon
|
10:45 |
How to Respond to FDA: Best Practices, Tips, Tricks, and Pitfalls to AvoidStephen Terman Companies will sometimes receive a written communication from FDA regarding either a pending product submission (e.g. a request for additional information), a compliance related matter (e.g. a 483 or a Warning Letter), or some other type of general communication (e.g. a letter to the industry regarding a policy change). It is important for companies to know how to go about responding to such communications in a way as to provide them with the best opportunity for successfully dealing with the issue at hand. 6 Join the Conversation ACI: Pharmaceutical/Biotech/Life Sciences @ACI_Pharma / #ACIFDA There is no one set of answers for every response. Often times the specifics of the response depend upon the type and substance of the communication, who in FDA sent it, the circumstances surrounding the issuance of the communication, as well as the regulatory history of the company. This presentation will provide valuable insights, gained from years of experience, and will cover the following topics:
|
11:30 |
Adverse Events Monitoring, Pharmacovigilance, Risk Management, and RecallsKatharine R. Latimer Linda Pissott Reig Jill Andersen
|
12:15 |
Conference Concludes** Luncheon will be served for delegates attending the afternoon Mater Classes beginning promptly at 12:15 |
1:15 |
Hatch-Waxman and BPCIA: Overview of Biosimilars and Life Cycle Planning for Drugs and Biologics1:15 Biosimilars James Czaban
2:30 Bioequivalence and the “Same Active Ingredient” vis-à-vis Patentability Clark G. Sullivan
3:30 Afternoon Refreshment Break 3:45 Marketing Exclusivities (Non-Patent): Challenges, Opportunities, and Current Controversies David Adams There are a number of different modes and methods of exclusivity
(non-patent). This session will outline what they are and what
5:00 Master Class B Concludes |